News

The progress of two promising experimental PAH therapies has led one of the two drug development companies working on them to part ways with a board member in order to avoid a conflict of interest. Mast Therapeutics, Inc. recently announced the resignation of Jack Lief from its board of directors.

Two theories behind the pathogenesis of pulmonary arterial hypertension (PAH) converge on the protein known as the master transcription factor forkhead box O1 (FoxO1). Leaders in the field of PAH research are excited about the notion that addressing master transcription factors may integrate the metabolic and inflammatory theories behind PAH,…

Worldwide, more than 64 million people are affected by Chronic Obstructive Pulmonary Disease (COPD) according to the World Health Organization, and in 2030 the condition will be third leading cause of mortality. COPD causes lung scarring, also called pulmonary fibrosis. The condition has no cure, and once the scarring has occurred,…

The U.S. Food and Drug Administration (FDA) has approved the extended use of a VMS Heart Analysis system developed and commercialized by the company VentriPoint Diagnosis, which is currently used in patients who suffer from pulmonary arterial hypertension (PAH). According to the…

The Pulmonary Hypertension Association (PHA), the US’s leading fundraising and advocacy group for funding scientific research to discover new ways to prevent and cure pulmonary hypertension (PH), will celebrate its 25th Anniversary in 2016. In celebration of that milestone and to continue the fight against the disease, the PHA has announced that…

Scleroderma has often been associated with a higher risk of pulmonary arterial hypertension (PAH) in previous research. This is because in patients with scleroderma, there is progressive blood vessel contraction (narrowing) that often leads to an increase in blood pressure in the lungs, which can in turn develop into PAH. This progression from…

In a case study published in the International Journal of Cardiology, a team of researchers from China reported the case of a 23-year-old woman with the absence of a right pulmonary artery and patent ductus arterioles who developed severe pulmonary hypertension. The researchers found that the use of …

Patients with systemic sclerosis (SSc) are at an increased risk for mortality due to concurrent pulmonary hypertension or interstitial lung disease. While pulmonary hypertension results in right-sided heart failure, interstitial lung disease results in extensive lung fibrosis. It may be possible to test for lung scarring using high resolution computed…

Representatives from Bayer HealthCare Pharmaceuticals presented findings at the American Thoracic Society’s (ATS) 2015 International Conference that suggest pulmonary hypertension is more prevalent in patients with pulmonary embolisms than was previously thought. Although the rate may be at least twice as high as previously identified, many patients do not undergo the…

Celsion Corporation, an oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies, recently announced an abstract publication in the Journal of Controlled Release. The abstract summarizes results from a preclinical trial which confirmed the effective…

In a recent study entitled “An excellent result of surgical treatment in patients with severe pulmonary arterial hypertension following mitral valve disease,” authors analyzed recent outcomes and mortality rates for patients with pulmonary arterial hypertension who underwent mitral valve surgery. They observed a significant decrease in the number of deaths…

Bayer HealthCare will deliver six presentations at the ongoing American Thoracic Society (ATS) International Conference in Denver, Colorado. Five posters and one oral presentation will describe data concerning treatment of patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). “At the American Thoracic Society…